Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Preliminary research has shown that a vaginal gel containing the antiretroviral (ARV) drug
tenofovir may reduce the risk of HIV infection in women when used near the time of sexual
intercourse. This study will evaluate the safety of 1% tenofovir gel in HIV-uninfected
pregnant women and their newborns when the gel is used once a day for a period of 28 days at
a designated time during pregnancy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)